The novelty of the current study lies in establishing an association between adiponectin, which is a marker of metabolic risk and an expanded steroid profile of androgen control, including two 11-oxygenated androgens, which are currently explored as potential superior markers of disease control in CAH.44,46 This suggests that adiponectin warrants further investigation through long-term follow-up studies as a predictor of metabolic problems in relation to androgen control in patients with CAH. Here, ADIPOQ is linked to congenital adrenal hyperplasia.